Page last updated: 2024-09-04

tezosentan and tbc-11251

tezosentan has been researched along with tbc-11251 in 4 studies

Compound Research Comparison

Studies
(tezosentan)
Trials
(tezosentan)
Recent Studies (post-2010)
(tezosentan)
Studies
(tbc-11251)
Trials
(tbc-11251)
Recent Studies (post-2010) (tbc-11251)
15729331673258

Protein Interaction Comparison

ProteinTaxonomytezosentan (IC50)tbc-11251 (IC50)
Endothelin receptor type BHomo sapiens (human)4.9049
Endothelin-1 receptorHomo sapiens (human)0.0014

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (50.00)29.6817
2010's2 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Berens, KL; Blok, N; Bourgoyne, AR; Brock, TA; Bui, H; Decker, ER; Dixon, RA; Holland, GW; Knowles, V; Wang, J; Wu, C; You, TJ1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Bolli, MH; Boss, C; Gatfield, J1
Lüscher, TF; Spieker, LE1

Reviews

2 review(s) available for tezosentan and tbc-11251

ArticleYear
From bosentan (Tracleer®) to macitentan (Opsumit®): The medicinal chemistry perspective.
    Bioorganic & medicinal chemistry letters, 2016, 08-01, Volume: 26, Issue:15

    Topics: Bosentan; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Humans; Molecular Structure; Pyrimidines; Receptors, Endothelin; Structure-Activity Relationship; Sulfonamides

2016
Will endothelin receptor antagonists have a role in heart failure?
    The Medical clinics of North America, 2003, Volume: 87, Issue:2

    Topics: Animals; Bosentan; Cardiovascular Agents; Clinical Trials as Topic; Endothelin Receptor Antagonists; Endothelins; Heart Failure; Humans; Isoxazoles; Oligopeptides; Peptides, Cyclic; Phenylpropionates; Piperidines; Pyridines; Pyrimidines; Sulfonamides; Tetrazoles; Thiophenes; Treatment Outcome

2003

Trials

1 trial(s) available for tezosentan and tbc-11251

ArticleYear
Discovery, modeling, and human pharmacokinetics of N-(2-acetyl-4,6-dimethylphenyl)-3-(3,4-dimethylisoxazol-5-ylsulfamoyl)thiophene-2-carboxamide (TBC3711), a second generation, ETA selective, and orally bioavailable endothelin antagonist.
    Journal of medicinal chemistry, 2004, Apr-08, Volume: 47, Issue:8

    Topics: Administration, Oral; Animals; Antihypertensive Agents; Biological Availability; Dose-Response Relationship, Drug; Double-Blind Method; Endothelin A Receptor Antagonists; Humans; Isoxazoles; Ligands; Male; Models, Molecular; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Structure-Activity Relationship; Sulfones

2004

Other Studies

1 other study(ies) available for tezosentan and tbc-11251

ArticleYear
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010